Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
life sciences
national
7
×
national blog main
national top stories
new york top stories
san francisco top stories
biotech
boston blog main
boston top stories
boulder/denver blog main
boulder/denver top stories
clinical trials
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
amgen
fda
novartis
cancer
eli lilly
fremanezumab
merck
roche
teva pharmaceutical
alder biopharmaceuticals
biogen
bristol-myers squibb
What
drug
7
×
new
7
×
fda
approval
approved
bio
class
companies
drugs
medicine
migraine
oral
patients
roundup
won
advantages
amgen
arguments
atrophy
bar
big
biogen’s
biopharmaceutical
brings
cancer
candidates
cholesterol
commercialized
competitors
convo
daily
decades
deeper
developed
dna
earlier
evrysdi
expect
expensive
faces
Language
unset
Current search:
drug
×
national
×
new
×
@xconomy.com
3 years ago
FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
New PCSK9 Cholesterol Drug Faces Tough Foe. (Hint: Not Cholesterol.)
@xconomy.com
5 years ago
At Big Neuro Meeting, Migraine Drug Competitors to Make Oral Arguments
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines